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ABSTRACT  
THE COMBINED EFFECTS OF GENISTEIN AND DAIDZEIN ON ADIPOCYTE 
DIFFERENTIATION  
MAY 2014 
OUMOU HABYBAT KONE, B.S., UNIVERSITE DE OUAGADOUGOU 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST  
Directed by professor Young-Cheul Kim  
 
Dietary soy isoflavones have been shown to ameliorate insulin resistance and Type 2 diabetes. 
However, many in vitro studies used supra-physiological concentrations of individual 
isoflavones that make it difficult to interpret the results as potential mechanisms in vivo. Since 
the insulin-sensitizing effects of thiazolidinediones, anti-diabetic drugs, have been shown to be 
mediated through activation of peroxisome proliferators-activated receptor gamma (PPARγ), the 
key transcription factor for adipocyte differentiation, we examined the effects of the two main 
soy isoflavones genistein and daidzein either as individual compound or combined on adipocyte 
differentiation and PPARγ expression, as well as whether the Wnt/β-catenin signaling pathway is 
the underlying molecular mechanism. In 3T3-L1 cells, genistein and daidzein significantly 
enhanced adipocyte differentiation. Similarly the expression of PPARγ increased particularly at 
20 µmol/L. The stimulatory effect is greater when the two isoflavones are combined, indicating a 
synergistic effect. Genistein and daidzein also increased the relative abundance of insulin-
responsive glucose transporter 4 (GLUT4) mRNA with a greater effect when combined. Wnt10b 
expression was not affected by soy isoflavones treatments, while Wnt5b expression was only 
increased by the combination of genistein and daidzein. Our results suggest, that the combination 
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of soy isoflavones has a greater effect in increasing the newly formation of adipocytes that are 
highly insulin-sensitive via an increase in PPARγ expression as well as increasing the expression 
of GLUT4. However, genistein and daidzein actions on Wnt signaling remain unclear. These 
data further support the epidemiological findings for the beneficial effect of soy consumption on 
insulin sensitivity.  
  
  
vi 
 
TABLE OF CONTENTS 
                                                                                                                                                    Page 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
ABSTRACT ................................................................................................................................... iv 
LIST OF TABLES ....................................................................................................................... viii 
LIST OF FIGURES ....................................................................................................................... ix 
CHAPTER                                                                                                                                       1 
BACKGROUND ............................................................................................................................ 1 
1.1 Overview ............................................................................................................................... 1 
1.2 T2DM: causes and risk factors .............................................................................................. 3 
1.3 Adipocyte differentiation ...................................................................................................... 3 
1.4 Failure of adipocytes to differentiate in T2DM .................................................................... 7 
1.5 The dietary soy isoflavones genistein and daidzein ............................................................ 10 
1.5.1 Sources, structure and metabolism ............................................................................... 10 
1.5.2 Bioavailability of isoflavonoids .................................................................................... 11 
1.5.3 Soy bioactives and health benefits ................................................................................ 12 
1.6. The Wnt/β-catenin signaling pathway and adipocyte differentiation ................................ 18 
EFFECT OF COMBINED GENISTEIN AND DAIDZEIN ON ADIPOCYTE 
DIFFERENTIATION ................................................................................................................... 21 
2.1 Literature Review ................................................................................................................ 21 
2.2 Purpose of study .................................................................................................................. 23 
2.3 Materials and Methods ........................................................................................................ 24 
2.3.1 Cell Culture Model and Treatments ............................................................................. 24 
2.3.2 Oil Red O Staining of Lipids ........................................................................................ 24 
2.3.3 RNA Isolation and Analysis ......................................................................................... 25 
2.3.4 Statistical Analysis ....................................................................................................... 25 
2.4 Results ................................................................................................................................. 26 
2.4.1 Effect of genistein, daidzein and their combination on adipocyte differentiation ........ 26 
2. 4.2 Correlation of adipocyte differentiation and adipogenic genes mRNA expression .... 27 
2.4.3 Effects of Genistein, daidzein and their combination on                                       
GLUT4 mRNA expression .................................................................................................... 32 
2.4.4 Effects of Genistein, daidzein and their combination on the                                       
Wnt signaling pathway .......................................................................................................... 34 
  
vii 
 
2.5 Discussion ........................................................................................................................... 38 
CONCLUSION & FUTURE DIRECTIONS ............................................................................... 40 
3.1 Summary ............................................................................................................................. 40 
3.2 Limitations .......................................................................................................................... 41 
3.3 Significance of Findings...................................................................................................... 42 
3.4 Future Research Directions ................................................................................................. 42 
REFERENCES ............................................................................................................................. 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
viii 
 
LIST OF TABLES 
Table                                                                                                                                          Page 
1. In vitro models of adipocyte differentiation (Source: GREGOIRE, SMAS, AND SUL Volume 
78) ................................................................................................................................................... 4 
2. Literature review ....................................................................................................................... 15 
3. Primer Information.................................................................................................................... 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ix 
 
LIST OF FIGURES 
Figure                                                                                                                                         Page 
Figure 1. Stages in adipocyte differentiation .................................................................................. 5 
Figure 2. Molecular events during adipocyte differentiation,......................................................... 7 
Figure 3. Regulation of adipose depot cell phenotype by thiazolidinedione activation of PPARγ 9 
Figure 4. Structure of soy isoflavones and their metabolites ........................................................ 11 
Figure 5. Schematic description of canonical Wnt signaling ....................................................... 19 
Figure 6. Genistein, daidzein and their combinations dose-dependently increased lipid 
accumulation in 3T3-L1 preadipocytes, as measured by Oil Red O staining. .............................. 27 
Figure 7. PPARγ mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) or 
their combinations (C). ................................................................................................................. 29 
Figure 8. C/EBPα mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) or 
their combinations (C). ................................................................................................................. 31 
Figure 9. GLUT4 mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) or 
their combinations (C). ................................................................................................................. 33 
Figure 10. Wnt5b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) or 
their combinations (C). ................................................................................................................. 35 
Figure 11. Wnt10b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) or 
their combinations (C). ................................................................................................................. 37 
 
 
 
  
1 
 
CHAPTER1 
BACKGROUND 
1.1 Overview 
The World Health Organization estimates that by the year 2025, there will be about 300 million 
individuals affected by Type 2 Diabetes Mellitus (T2DM) worldwide [1]. T2DM is a disorder of 
glucose and lipid metabolism, contributing to the development of severe health complications 
including disorders of microvascular system (retinopathy, neuropathy and nephropathy) and 
macrovascular system (coronary heart disease, atherosclerosis and stroke). These complications 
lead to a significant reduction in quality of life and account for the excess mortality; more than 
75% of people with T2DM die prematurely of cardiovascular disease [2]. Insulin resistance, an 
inability of insulin to stimulate glucose utilization in insulin target tissues such as adipose and 
muscle is considered to be the primary metabolic defect of T2DM and is highly correlated with 
obesity; enlarged adipocytes in obesity are shown to be defective in insulin signaling and thus 
insulin resistant, predisposing to T2DM [3].  In addition, the impairment of proliferation and 
differentiation of adipocytes has been reported in insulin resistant subjects [4]. Thus, insulin 
resistance and T2DM can be triggered by a failure of adipocytes to differentiate into new 
adipocytes. Thiazolidinediones (TZD), a class of anti-diabetic drugs improve glycemic control 
by activating a nuclear receptor peroxisome proliferator activated receptor-γ (PPARγ), which is 
highly expressed in adipose tissues and also a key regulator of adipocyte differentiation. In 
insulin resistant fat depots, TZD have been shown to enhance adipocyte differentiation and 
opposes the actions of adipokines that mediate insulin resistance [5]. The metabolic effects of 
TZD include enhanced insulin signaling, resulting in increased glucose uptake and metabolism 
  
2 
 
coupled with reduced release of free fatty acids into the circulation. One of the mechanisms of 
TZD to increase insulin sensitivity is to enhance the differentiation with small and insulin-
responsive adipocytes. However, their strong affinity for PPARγ, has been shown to promote 
weight gain, an adverse side effect of the drugs [6; 7]. Thus, there have been increasing efforts 
to identify natural compounds with fewer side effects [8]. Epidemiological data strongly suggest 
that consumption of plant-based foods rich in isoflavones like soybeans provide beneficial 
effects for human health [9]. Animal and human studies have been conducted to investigate 
anti-diabetic effects of soybeans and their actions [10; 11; 12; 13]. Soya-containing diets were 
associated with an improvement in insulin resistance, glycemic control and weight loss [14]. 
The biological action of isoflavones involves several mechanisms of action and cellular 
signaling pathways such as the Wnt/β-catenin signaling pathway that represses adipogenesis 
[15]. Although individual effects of isoflavones on adipocyte differentiation have been studied, 
most of the studies have considered supra-physiological concentrations; however, it is not clear 
whether the combination of the two main soy isoflavones has a synergistic effect on adipocyte 
differentiation and insulin sensitivity, and whether the effect is mediated by the Wnt/β-catenin 
signaling pathway. Therefore, our focus was to determine in 3T3L-1 mouse pre-adipocytes, (1) 
the extent to which the combination of low doses of genistein and daidzein affect adipocyte 
differentiation and insulin sensitivity; and (2) the extent to which the Wnt/β-catenin signaling 
pathway is the molecular mechanism through which genistein and daidzein treatment promote 
adipocyte differentiation and insulin sensitivity.  
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1.2 T2DM: causes and risk factors 
T2DM is characterized by hyperglycemia and hyperlipidemia [16–18]. It prevalence has reached 
epidemic proportions worldwide [19]. In the U.S, the incidence of T2DM has increased by about 
33% over the past decade [20, 21]. Obesity and insulin resistance strongly predispose an 
individual to T2DM with a progressive increase of fasting glucose levels. According to the 
WHO, 44% of the diabetes burden, is attributable to overweight and obesity [22]. Insulin 
resistance is a major feature of T2DM and develops in multiple organs, including adipose tissue. 
The onset of hyperglycemia and T2DM is often preceded by many years of insulin resistance. 
Obesity plays a pivotal role in this phenomenon, providing an important link between fat cell 
accumulation and differentiation and T2DM [23]. Newly formed adipocytes are highly insulin 
sensitive and less inflammatory, while old adipocytes are associated with an increase in pro-
inflammatory response, which can promote insulin resistance [5]. The inability of adipocyte 
differentiation to replace poorly functioning adipocytes has been identified in common metabolic 
diseases such as T2DM and obesity. It has been shown that approximately 10% of adipocytes 
turn over in human adipose tissue each year, which indicates that ensuring the healthy newly 
formed adipocytes could substantially improve metabolic diseases [23].  
 
1.3 Adipocyte differentiation 
White adipose tissue is the major energy reserve in higher eukaryotes, and storing triacylglycerol 
in periods of energy excess and its mobilization during energy deprivation are its primary 
purposes. It is also considered to be secretory organ releasing factors called adipokines that 
regulate several physiological processes. For the past twenty years, many in vitro studies have 
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been conducted to investigate various molecular aspects of adipocyte differentiation. Various 
pre-adipocyte cell lines and primary fat cells cultures have been used. Table 1 summarizes the 
characteristics of the most commonly employed pre-adipocyte cell models. 
 
Table 1. In vitro models of adipocyte differentiation (Source: GREGOIRE, SMAS, AND SUL 
Volume 78) 
 
Cell Lines Origin/Stage of Development Inducing Agents Used for 
Differentiation 
Reference 
Number 
CH3 10T/1/2 
 
 
3T3-L1 
 
 
3T3-F442A 
 
Ob17 
Mouse embryo† 
 
 
17- to 19-day disaggregated mouse 
embryo 
 
 
Same as above  
 
Epididymal fat pads of adult ob/ob 
mouse 
Demethylating agent 5*-
azacytidine 
 
 
10% FBS, Dex and MIX, 
insulin (high concentration) 
 
10% FBS, insulin  
 
8% FBS, insulin, and T3  
 
4,5 
 
 
6 
 
 
7,8 
 
 
9 
Primary 
Cultures 
Sources/Age Inducing Agents used for 
Differentiation 
Reference 
Rat 
 
 
 
Mouse 
 
Rabbit 
 
 
 
Human 
Subcutaneous, epididymal, 
retroperitoneal/newborn  
(48 h), 4 wk old, or adult 
 
Subcutaneous/8–12 day old  
 
Perirenal/4 wk old  
 
 
 
Subcutaneous (abdominal)/ variable age 
Insulin (low concentration in 
10% FBS, high concentration in 
serum free, accelerated)  
 
Serum free; insulin, HDL, Dex  
 
Serum free; insulin, Dex 
 
 
Serum free; insulin (high 
concentration) and 
glucocorticoids 
10, 11, 12,  
 
 
 
13 
 
 
14 
 
 
 
 
15,16,10 
FBS: fetal bovine serum; MIX, methylisobutylxanthine; Dex: dexamethasone; HDL, high-density lipoprotein; * Totipotent cell 
line. † Multipotent.   
 
 
Owing to their convenience and traceability, pre-adipocyte cell lines like 3T3-L1 have been used 
widely to study pre-adipocyte biology. Even though, primary cell lines reflect better the in vivo 
context due to their pluripotency stage, they do not undergo continuous passage. Moreover, 
proliferation and differentiation of primary pre-adipocytes is influenced by the anatomic site of 
the depots and the age of the donor. In particular, aging reduces replicative ability of primary 
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pre-adipocytes in cell culture [Djian et al., 1983]. Importantly, clonal cell lines like 3T3-L1 are 
homogenous in terms of cellular population, and their cell types are all at the same differentiation 
stage [24].  This allows a homogeneous response to treatments. Besides, these cells can be 
passaged indefinitely, which provides a consistent source of pre-adipocytes for study. For all 
these reasons, we have chosen 3T3-L1 cells as a cell model for this study. 
 
During the growth phase, cells of pre-adipocyte lines are morphologically similar to fibroblasts. 
At confluence, induction of differentiation by appropriate treatment leads to drastic cell shape 
changes. The pre-adipocytes are converted to a spherical shape, accumulate lipid droplets, and 
progressively acquire the morphological and biochemical characteristics of the mature white 
adipocyte (Figure 1, [25]). The nature of the induction is dependent on the specific cell culture 
model system employed (confer Table 1).  
 
 
 
Multipotent 
o Chrondoblast 
o Osteoblast 
o Myoblast 
Determined 
o Growth arrest 
o Post-confluent  mitoses 
o Myoblast 
Commited 
Terminal differentiation 
 
Figure 1. Stages in adipocyte differentiation 
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During adipocyte differentiation, acquisition of the adipocyte phenotype is characterized by 
chronological changes in the expression of numerous genes (Figure 2). This is reflected by the 
appearance of early, intermediate, and late markers and triglyceride accumulation. These changes 
take place primarily at the transcriptional level, although post-transcriptional regulation occurs 
for some adipocyte genes [26].  
 
Two transcription factors, CCAAT/enhancer binding protein alpha (C/EBPα) and PPARγ, have 
been shown to transactivate adipocyte specific genes. During the terminal phase of 
differentiation, adipocytes in culture markedly increase de novo lipogenesis and acquire 
sensitivity to insulin. The activity, protein, and mRNA levels for enzymes involved in 
triacylglycerol metabolism include: ATP citrate lyase, malic enzyme, acetyl-CoA carboxylase, 
stearoyl-CoA desaturase (SCD1), glycerol-3- phosphate acyltransferase, glycerol-3-phosphate 
dehydrogenase, fatty acid synthase, and glyceraldehyde-3-phosphate-dehydrogenase increase 10- 
to 100-fold [ 27, 28]. Glucose transporters [29], insulin receptor number, and insulin sensitivity 
increase with the degree of differentiation. In addition to increases in gene expression directly 
related to lipid metabolism, adipocytes also synthesize other adipose tissue-specific products 
involved in fatty acid transport. These include the following: aP2, an adipocyte specific fatty acid 
binding protein; FAT/CD36, a putative fatty acid transporter [30,31]. 
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1.4 Failure of adipocytes to differentiate in T2DM 
A major function of the adipose organ is to store excess energy as triglycerides under conditions 
of nutrient excess [32]. However, in response to prolonged periods of calorie excess, the adipose 
organ may become overloaded and unable to recruit new fat cells, resulting in adipose tissue 
hypertrophy of existing fat cells and increased ectopic fat deposition in tissues such as skeletal 
muscle, liver, myocardium, and pancreas. Fat depots consist of multiple cell types. In addition to 
fully differentiated mature adipocytes that are able to synthesize fatty acids, metabolize glucose, 
and take up and store triglyceride from the blood, adipose tissues contain multipotent precursor 
Figure 2. Molecular events during adipocyte differentiation,  
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cells that can be induced to differentiate into mature adipocytes. The adipocyte population within 
a fat depot ranges from small, newly differentiated, highly insulin responsive adipocytes to large, 
lipid-filled, relatively insulin resistant adipocytes. In insulin resistant states, such as obesity and 
T2DM, fat depots contain a high proportion of large-lipid filled adipocytes. For example, 
independent of total body fat, Pima Indians with larger abdominal fat cells are more insulin 
resistant and more likely to develop diabetes than those with smaller fat cells [33; 34]. People 
with enlarged subcutaneous adipocytes are more hyperinsulinemic and glucose intolerant and are 
at increased risk for the development of T2DM, relative to those with similar degrees of 
adiposity but smaller adipocytes. It has been hypothesized that insulin resistance develops 
because of alterations in the partitioning of fat between adipose tissue and muscle or liver [35]. It 
is also known that a lack of adipose tissue is similarly associated with insulin resistance and 
increased risk for development of T2DM [36; 37]. Similarly, in humans, lipodystrophy is 
associated with insulin resistance and often T2DM [38].  
 
The anti-diabetic drug TZD constitutes a good example of how adipocyte differentiation can 
reverse insulin resistance. These drugs act by activating PPARγ in fat depots, which potentiates 
the insulin-mediated differentiation program, resulting in increased number of small insulin-
sensitive fat cells. In large, insulin resistant adipocytes, TZD opposes pro-inflammatory cytokine 
production and promotes apoptosis (Figure 3), [5].  
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Although TZD is effective in reducing insulin resistance and thus treating T2DM, an important 
drawback is that they increase weight gain because of excessive adipocyte differentiation 
(insulin-sensitive small adipocytes). It is important, therefore, to continue to research safer 
alternatives to TDZ. For example, it is known that soy-rich diets decrease weight gain and 
insulin resistance; therefore, they might constitute a safer alternative to treat insulin resistance 
and T2DM. Discovery of the molecular mechanism through which increased soy consumption 
bring about these favorable effects is not completely understood. In particular, the importance of 
bioactive compounds found in soy, such as genistein and daidzein, on adipocyte differentiation 
require additional investigation. 
 
 
 
  
Pre-adipocytes Insulin-responsive small 
adipocytes 
PPARγ 
TZD 
Potentiates insulin 
stimulated differentiation 
Blocks lipolysis and 
inflammatory cytokines 
release. Pro-apoptotic 
Insulin-resistant  
large adipocytes 
Figure 3. Regulation of adipose depot cell phenotype by thiazolidinedione activation 
of PPARγ  
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1.5 The dietary soy isoflavones genistein and daidzein 
 
1.5.1 Sources, structure and metabolism  
Isoflavones are a class of polyphenols that are biologically active plant-derived compounds. 
Many of them structurally and functionally mimic estrogens [39] and, therefore, are called 
phytoestrogens. Isoflavones are mainly found in the soybean—the most important dietary source 
of phytoestrogens for humans, cattle and rodents. They have a non-steroidal structure, but 
possess a phenolic ring that enables them to bind to the estrogen receptor (ER) and act either as 
estrogen agonists or antagonists [40; 41]. The three principal isoflavones found in soy are 
genistein, daidzein and glycetein, generally in a concentration ratio of 1:1:0.2 [42]. Genistein 
(4,5,7-trihydroxyisoflavone) and daidzein (4',7-Dihydroxyisoflavone), the most abundant  
isoflavones in soybean, are also present in several other plants which represent excellent sources 
of phytoestrogens such as lupine (Lupinus spp.), favabean, (Viciafaba) and kudzu (Pueraria 
lobata) [43]. After ingestion, genistein and daidzein are respectively released from the glucoside 
genistin and daidzin by acid hydrolysis in the stomach or by microflora hydrolysis in the 
intestine. The resulting aglycone from genistein can either be absorbed or further metabolized to 
specific metabolites (Dihydrogenistein, 5-hydroxy-equol) [44]. Daidzein can be converted to its 
end metabolite S-equol [7-hydroxy-3-(49-hydroxyphenyl)-chroman] in some humans based on 
the presence of certain intestinal bacteria.  
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(source: http://www.isoflavones.info/isoflavones-metabolism.php)   
 
1.5.2 Bioavailability of isoflavonoids 
Isoflavones are absorbed only as aglycones in the intestine and the glycosylated isoflavones can 
be hydrolyzed to the aglycone forms by β-glucosidases associated with gut bacteria and by 
lactase enzyme in the small intestine [45]. Studies on metabolism and bioavailability of 
isoflavonoids have been contradictory regarding the absorption of aglycones versus glycosides. It 
was reported that soy isoflavone aglycones are better absorbed than their corresponding 
glucosides in Japanese men and women [46]. Peak plasma concentrations were 4 times higher 
and occurred 2h earlier for both genistein and daidzein than for their glucoside counterparts. 
However, another study has shown that the apparent bioavailability of genistein and daidzein 
was not different when consumed as either raglycone or glucoside by American women [47]. 
Moreover, a better absorption of daidzein when consumed as a glucoside, where the fractional 
absorption of the daidzein aglycone was 11.6 versus 38.9 for the glucoside has been suggested 
[48]. A plausible explanation for this controversy is that isoflavone metabolism is more complex 
Figure 4. Structure of soy isoflavones and their metabolites  
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than it appears since it depends on many other factors related mainly to individuals and their 
diets. Food matrix/diet, dose, frequency of ingestion, age, gender, microfloral subgrouping and 
gut transit time are factors influencing metabolism and bioavailability of isoflavones and 
therefore should be taken into account when performing clinical trials with isoflavones [49]. 
 
1.5.3 Soy bioactives and health benefits 
Epidemiological data strongly suggest that consumption of plant-based foods rich in isoflavones 
provides beneficial effects for human health [44]. Thus, much attention has been given to 
investigating the effects of these compounds in human physiological and pathological states. 
Soybean contains between 0.6 and 3.8g isoflavones/kg fresh weight [50]. In populations having a 
high soy diet like the Japanese population, the plasma concentration of soy isoflavones can reach 
2.4 µmol/L [51]. In humans, plasma or serum levels of genistein from soyfood ingestion range 
from less than 1 µmol/L to about 5 µmol/L (Wiseman et al., 2004). Phytoestrogen intake varies 
from 20–50 mg/day in East and Southeast Asia to 0.15–3mg/day in the US and 0.49–1mg/day in 
some European countries (Klein and King, 2007), thus the safety dose was retained as 50 
mg/day. Daidzein and genistein exert various actions in the organism, mainly related to 
ameliorating some post-menopausal problems, such as hot flushes and bone loss, preventing 
breast cancer, reducing risk of cardiovascular diseases and affecting insulin secretion and action 
[52; 53; 54]. The complexity of their biological action suggests the involvement of several 
mechanisms of action and cellular signaling pathways such as estrogen-like activity, tyrosine 
kinase inhibitory effect, 5'AMP-activated protein kinase (AMPK) pathway and Wnt signaling 
pathway.  
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In a short (8 weeks) randomized crossover clinical trial including 42 post-menopausal women 
with the metabolic syndrome[10], soy nut consumption (soy nut-DASH diet) significantly 
decreased the homeostasis model of assessment-insulin resistance score compared with the 
control group on a red meat-DASH diet (-12.9±0.9; P< 0.01). Consumption of soy-nut also 
reduced fasting plasma glucose more significantly than did the control diet (-5.1±0.6%; P<0.01). 
The soy-nut regimen decreased LDL cholesterol more than did the control diet (-9.5±0.6%; 
P<0.01), and significantly reduced serum C-peptide concentrations compared with control diet (-
8.0±2.1; P<0.01).  In a double-blind controlled trial [10], 39 postmenopausal women were 
randomized to soy supplementation (20g soy protein plus 160mg isoflavones with 96mg 
available as aglycones) or to a casein placebo without isoflavones for 3 months. Soy 
supplementation reduced total and subcutaneous abdominal fat, and IL-6. No difference between 
groups was noted for glucose metabolism, CRP, TNF-α, leptin, or adiponectin.                        
The effects of soy isoflavone on insulin sensitivity and adipocytokines in high-fat-diet-induced 
insulin resistant (IR) rats were studied by using 80 male Sprague Dawley rats [11]. The rats were 
randomly assigned into a basal diet fed group and high-fat diet fed group. The high-fat-diet-
induced insulin resistant rats were assigned into IR model control group and three soy 
isoflavones-treated groups with different dosages. 30 days later, the fasting blood glucose, 
insulin and adipocytokines in serum and mRNA expressions of adipocytokines in perirenal white 
adipose tissue were measured. The Homeostasis Model Assessment of IR was calculated. The 
administration of 450 mg kg (-1) d (-1) soy isoflavones decreased the body weights and 
depositions of visceral adipose tissue as well as improved insulin resistance in high-fat-diet-
induced IR rats. The mechanisms were associated with soy isoflavones-regulating the expression 
of adipocytokines, including adiponectin, leptin, resistin and TNF-α. 
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In a randomized trial including 77 subjects for 12 months [12], a soy-based meal replacement 
(MR) plan showed a significant decrease in percentage weight loss (4.577 ±0.81%) compared 
with an individualized diet plan (IDP; as recommended by the American Diabetes Association) 
(2.257±0.72%). Controlling for baseline levels, hemoglobin A1C level improved by 
0.497±0.22% for those receiving MR when compared to IDP group (P<0.05). A greater number 
of subjects in MR group reduced their use of sulfonylureas (P<0.0001) and metformin (P<0.05) 
as compared to IDP group. High-sensitivity C-reactive protein (hs-CRP) decreased by 25.0% 
(P¼0.019) in MR group compared to 18.7% (P¼0.179) in IDP group at 12 months.        
Genistein (0.02%, w/w) and daidzein (0.02%, w/w) supplements increased insulin/glucagon ratio 
and C-peptide level with preservation of insulin staining β-cell of pancreas in the NOD mice 
[55]. In the liver, genistein and daidzein supplements resulted in lowering glucose-6-phosphatase 
and phosphoenolpyruvate carboxykinase activities, while increasing two lipogenic enzymes 
activities, malic enzyme and glucose-6-phosphate dehydrogenase, compared to the control 
group. Significantly, genistein and daidzein supplementation lowered the activities of fatty acid 
β-oxidation and carnitine palmitoyltransferase in these mice. Genistein and daidzein also 
improved plasma triglyceride and free fatty acid concentrations compared to the control group. 
Table 2 summarizes the state of art in soy isoflavones effects on adipogenesis. 
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Table 2. Literature review 
Human/Animal/Cell 
Lines 
Compounds/ 
Concentrations 
Author/Year 
 
Effects Mechanisms 
described 
 
Ovariectomized rats 
Daidzein/50mg/kg BW Cao YC et al. /2013 
 
Decrease weight gain, 
visceral fat and IL-6 
levels induced by 
ovariectomy.  Lower 
levels of TNF-alpha, 
leptin and blood lipids 
compare to the control 
group 
 
Ovariectomized rats Genistein/ 0.1% Joo Sun Choi et al. 
/2012 
 
Smaller adipocytes size, 
decrease insulin resistance 
index, increase hepatic  
fatty acid synthetase 
activity, increase 
succinate dehydrogenase 
activity and rate of β 
oxidation in fat tissues 
 
Freshly isolated 
Rat adipocytes 
Genistein/ 50 µMol Szkudelska et 
al./2011 
 
Inhibition of insulin-
stimulated glucose uptake 
and reduction of ATP 
levels 
 
C57BL/6J mice Daidzein/  0.1; 0.5; 1 and 
2 g per kg diet 
Kim, MH /2011 
 
Lower insulin and blood 
glucose levels. Inhibit 
adiposity, augment 
antisteatohepatitic leptin 
and adiponectin mRNA 
levels, reduce the mRNA 
or concentration of 
steatotic tumor necrosis 
factor a and ghrelin 
Down regulation of 
carbohydrate 
responsive element 
binding protein, its 
upstream gene liver 
X receptor beta and 
its target genes 
encoding for 
lipogenic enzymes 
Obese post-
menopausal women 
Genistein/ 60.8mg/day Llaneza et al. /2011 
 
Reduction of serum leptin 
levels 
Mitochondrial 
dysfunction 
Human adipose 
tissue-derived 
mesenchymal stem 
cell 
Genistein/ 100 µMol Kim et al. /2010 
 
Inhibition of adipogenic 
Differentiation 
Wnt/β–catenin 
signalingpathway 
Murine adipocytes genistein40 µMol Niwa et al./2010 
 
Inhibition of leptin 
secretion 
 
Primary human 
preadipocytes 
Genistein 50 µMol Park et al./2009 
 
Inhibition of lipid 
accumulation 
Down-regulation of 
PPARγ, C/EBPα and 
glycerol-3-phosphate 
dehydrogenase 
3T3-L1 adipocytes Genistein with vitamin D 
 
Rayalam et al./ 2008 
 
Inhibition of lipid 
accumulation and 
induction of apoptosis 
Suppression of 
PPARα, C/EBPα, and 
enhancing 
vitamin D receptor 
expression 
Human cells 
3T3L1 cells 
Genistein/6.25 µMol 
+Quercetin/12.5 µMol 
+Resveratrol/12.5 µMol 
 Enhance Inhibition of 
lipid accumulation and 
decrease glycerol-3-
phosphate activity 
compare to individual 
 
Rat adipocytes Genistein/ 100 µMol Szkudelska et 
al./2008 
 
Inhibition of the 
antilipolytic 
action of insulin 
Activation of protein 
kinase A and 
elevation of cAMP 
levels 
3T3-L1 adipocytes Genistein 10 µMol Nomura et al. /2008 
 
Abrogation of GLUT4 
mediated 
glucose uptake 
Tyrosine kinase 
inhibition activity 
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3T3-L1 adipocytes Genistein with resveratrol Rayalam et al. /2007 
 
Inhibition of 
adipogenesis;  induction 
of apoptosis; and 
stimulation of lipolysis 
Down-regulation of 
PPARγ  and C/EBPα 
 
Non-obese diabetic  
mice 
genistein (0.02%,w/w)  
 
daidzein (0.02%, w/w) 
Choi et al. / 2007 
 
Lower Blood glucose 
levels by about 40%,  
increase insulin/glucagon 
ratio and C-peptide level 
with preservation of 
insulin staining β-cell of 
pancreas,  o improved 
plasma triglyceride and 
free fatty acid (FFA) 
concentrations 
 
3T3-L1 adipocytes Genistein with 
Guggulsterone 
Yang et al./ 2007 
 
Apoptosis and 
suppression of 
differentiation and 
adipogenesis 
Production of active 
caspase3. Expression 
of pro-apoptotic Bax. 
Release of 
cytochrome c 
Ovariectomized 
C57/BL6 
female mice 
Genistein 1,500 mg/kg Kim et al./2006 
 
Reduction of food 
intake,body 
Weight and fat pad 
weight. 
 
3T3-L1 mouse 
embryo fibroblasts 
Genistein 400 µMol Kim et al./2006 
 
Adipose tissue apoptosis  
MC3T3-
G2/PA6adipocytes 
Genistein 50 µMol Bazuine et al./2005 
 
Inhibition of glucose 
uptake 
Tyrosine kinase 
inhibition activity 
3T3-L1 adipocytes Genistein 100 µMol Harmon and 
Harp/2001 
 
Increased lipolysis  
3T3-L1 adipocytes Genistein 200 µMol Hwang et al./2005 
 
Inhibition of adipocyte 
differentiation 
Activation of AMP-
activated 
protein kinase 
3T3-L1 
adipocytes 
Genistein with green tea 
catechin andcapsaicin 
Hwang et al. /2005 
 
Suppression of 
differentiation, 
adipogenesis and lipid 
accumulation, and 
induction of apoptosis 
Release of 
intracellular reactive 
oxygen species and 
activation of AMPK 
pathway 
 
Physical activity, diet and daily oral intake of a soy isoflavones extract, that contains 60.8mg of 
genistein, have shown beneficial effect on serum leptin, adiponectin and TNFα in healthy obese 
post-menopausal women after 6 months of treatment compared with a control group [56].         
Twelve weeks of daidzein therapy (50mg/kg/day) decreased weight gain, visceral fat, the 
HOMA-IR index and IL-6 levels in ovarectomized rats compare with the control group. Rats 
which had received daidzein therapy had lower levels of TNF-α, leptin and blood lipids. IL-6 
levels positively correlated with the HOMA-IR index in all of the rats after adjustment for body 
weight (r =0.495; p =0.016) [57].                                                                                                  . 
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In 3T3-L1 cells, daidzein enhanced adipocyte differentiation and PPARγ expression in a dose-
dependent manner. It also dose-dependently increased insulin-stimulated glucose uptake and the 
relative abundance of insulin-responsive glucose transporter 4 (GLUT4) and insulin receptor 
substrate 1 (IRS-1) mRNA. In C3H10T1/2 mouse cells, daidzein at 1 µmol/L and higher 
significantly increased adipocyte differentiation and insulin-stimulated glucose uptake [58]. 
Furthermore, daidzein also up-regulated PPARγ-mediated transcriptional activity, and restored 
the PPARγ antagonist-induced inhibition of aP2 and GLUT4 mRNA levels.  
In mice, genistein supplementation improved hepatic steatosis and gene expression involved in 
the fatty acid catabolism (59, 60).  
Most of the in vitro studies about genistein effects on adipogenesis have considered high 
concentrations that inhibit adipocyte differentiation and increase lipolysis. Yang et al., 2007, 
showed that genistein alone (50µmol/L and 100µmol/L) or in combination with guggulsterone 
(25µmol/L and 50µmol/L) suppressed differentiation, adipogenesis and lipid accumulation in 
3T3-L1 adipocytes. The same observation was found with genistein at 50, 100 and 200µmol/L in 
3T3L-1 adipocytes (Hwang et al., 2005). Concerning the mechanisms involved, Kim et al., 2010, 
reported that genistein inhibited adipogenic differentiation of human adipose tissue-derived 
mesenchymal stem cell via Wnt/β-catenin signaling pathway, in an estrogen receptor-dependent 
manner. Lipid accumulation was also inhibited by genistein in a dose dependent manner, through 
down-regulation of adipocyte specific transcription factors such as PPARγ, C/EBPα and 
glycerol-3-phosphate dehydrogenase (Park et al., 2009).  
The supra-physiological concentrations of genistein used in these studies above, result in 
decreased adipogenesis and increased lipolysis. However, increasing lipolysis lead to an increase 
release of free fatty acid which triggers insulin resistance and inflammation. Therefore, finding a 
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safer way to prevent obesity and the metabolic syndrome is needed. While clinical studies have 
shown beneficial effects of soy isoflavones supplementation in both weight loss and insulin 
sensitivity, none of the studies have considered looking at a potential synergism of action 
between the main soy isoflavones genistein and daidzein. Xin Dong et al., 2013 showed that 
daidzein and genistein have a synergistic effect on inhibiting cell proliferation and inducing 
apoptosis of prostate cancer cells. 25 µmol/L daidzein/ 50 µmol/L genistein significantly 
increased the apoptotic effects on C4-2B cells although they did not show any effect when used 
individually. We hypothesized that genistein and daidzein will have synergistic action in 
promoting insulin sensitivity via an increase in the master regulator of adipocyte differentiation, 
PPARγ and a down regulation of specific Wnt proteins. The expression of PPARγ has been 
shown to be influenced by the Wnt/β-catenin signaling pathway [61]. 
 
1.6. The Wnt/β-catenin signaling pathway and adipocyte differentiation 
The field of adipogenesis has seen an increase in the number of reports involving locally secreted 
or circulating extracellular factors as regulators of pre-adipocyte differentiation [62]. One of the 
extracellular signaling pathways now known to affect adipogenesis is the Wnt pathway.         
Wnt are an evolutionarily conserved family of secreted lipidated glycoproteins with well-
established roles in cellular proliferation, differentiation, and polarity during embryogenesis [63, 
64]. More recently, Wnt signaling has been shown to modulate additional developmental and 
physiological processes, including aspects of adipocyte biology [65; 66]. Although Wnt can 
inhibit pre-adipocyte differentiation through both β-catenin-dependent and independent 
mechanisms [15], current genetic evidence supports β-catenin as a particularly crucial regulator 
of adipogenesis [67]. In Wnt/β-signaling pathway, β-catenin plays a central role as a 
  
19 
 
transcriptional co-activator. Upon binding of Wnt ligands to frizzled receptors and low density 
lipoprotein receptor-related protein (LRP) co-receptors, cytoplasmic β-catenin is 
hypophosphorylated, stabilized, and translocated into the nucleus where it binds to and co-
activates members of the T-cell factor/lymphoid-enhancing factor (TCF/LEF) family of 
transcription factors to direct target gene expression (Figure 5, [68]). 
 
Figure 5. Schematic description of canonical Wnt signaling 
 
 
 
In vitro and in vivo data characterized the role of Wnt-signaling molecules in the regulation of 
adipocyte differentiation. In human and murine pre-adipocytes, a down-regulation of Wnt/β-
signaling is a prerequisite in order to initiate adipogenesis. Over-expression of Wnt10b in mouse 
pre-adipocytes inhibited the expression of C/EBPα and PPARγ and kept pre-adipocytes in an un-
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differentiated state in vitro and in vivo [69]. Conversely, inhibition of Wnt-signaling was 
sufficient to facilitate spontaneous differentiation of adipocytes and trans-differentiation of 
myoblasts into adipocytes. Cawthorn et al. demonstrated that suppression of C/EBPα and PPARγ 
by TNFα coincides with enhanced expression of several downstream targets of Wnt/β-catenin 
signaling [61]. Transgenic over-expression of Wnt10b in mice, under the control of the FABP4 
promoter led to a tissue specific expression of Wnt10b in white adipose tissue. These mice were 
found to have less adipose tissue on normal carbohydrate diet. Human genetic studies have 
revealed an association of a heterozygous loss of function mutation (C256Y) in the Wnt10b gene 
with obesity. Mature human primary adipocytes were found to secrete Wnt10b and Wnt3a and to 
inducel Wnt/β-signaling in target cells [70]. Isoflavones at supra-physiological concentrations 
can exert their anti-adipogenic effect through Wnt-signaling pathway.  
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CHAPTER 2 
EFFECT OF COMBINED GENISTEIN AND DAIDZEIN ON ADIPOCYTE 
DIFFERENTIATION  
 
2.1 Literature Review 
Diabetes mellitus is the most prevalent metabolic syndrome world-wide with an incidence 
varying between 1 to 8% [73, 74]. In the US, the incidence of T2DM has increased by about 
33% over the past decade and is expected to increase further [75, 76]. The disease arises when 
insufficient insulin is produced, or when the available insulin does not function properly. Thus 
diabetes is characterized by hyperglycemia resulting in various short-term metabolic changes in 
lipid and protein metabolism and long-term irreversible vascular changes. Currently available 
therapies for diabetes include insulin and various oral anti-diabetic agents such as sulfonylureas, 
biguanides, α-glucosidase inhibitors, thiazolidinedione and glinides, which are used as 
monotherapy or in combination to achieve better glycemic regulation. Many of these oral anti-
diabetic agents suffer from various adverse effects, thus, managing diabetes without any side 
effects is still a challenge, and the search for more effective and safer therapeutic agents in 
eradiating diabetic syndromes is much needed. Dietary factors that enhance insulin sensitivity 
are a novel approach to treat the onset of metabolic disorders such as diabetes and obesity. 
Therefore, the identification and characterization of natural compounds which could improve 
insulin sensitivity is important for the treatment and prevention of T2DM. Soy is an important 
agricultural crop in the U.S that could have important health benefits. Clinical and 
epidemiological studies have shown that soy intake is associated with reduced incidence of 
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diabetes and T2DM-related symptoms [77, 78]. Dietary supplementation with isoflavones 
reduced insulin resistance and improved glycemic control in T2DM patients and also lowered 
low density lipoprotein cholesterol [79]. Soy isoflavones have been also shown to improve 
glucose tolerance and decrease blood glucose levels in diabetic animal models [80]. These 
studies indicate that soy isoflavones may enhance insulin sensitivity. However, the molecular 
mechanisms by which isoflavones sensitize the insulin-responsive tissues remain unclear. 
Adipose tissue is an important site of both glucose and lipid metabolism. Insulin resistance is 
associated with obesity. Systemic insulin resistance is observed in mice lacking insulin-sensitive 
glucose transporter 4 (GLUT4) in adipose tissue, suggesting that glucose metabolism in 
adipocytes is critical to whole-body glucose homeostasis [81]. Insulin responsiveness is acquired 
during the maturation phase of adipogenesis and involves the expression of proteins responsible 
for the phenotypic functions of adipocytes, such as GLUT4 [81]. Several genes related to 
adipocyte differentiation are decreased in Type 2 diabetic humans [82], suggesting that altered or 
impaired adipocyte differentiation may promote the onset of insulin resistance. PPARγ is a key 
regulator of adipocyte differentiation [25]. In addition to its regulatory role in adipogenesis, 
PPARγ activation modulates the expression of several key molecules involved in insulin 
signaling, lipid metabolism and endocrine function in adipocytes. It has been shown that PPARγ 
activation mediates the anti-diabetic activities of thiazolidinediones (TZDs) [5]. Dietary 
isoflavones has been found to increase PPARγ and GLUT4 protein in adipose tissue and reduced 
the severity of diabetes in Zucker diabetic fatty rats [80]. Although individual effects of 
isoflavones on adipogenesis have been studied, most of the studies have considered supra-
physiological concentrations and none of them has considered the effect of the combination of 
the two main soy isoflavones on adipocyte differentiation and insulin sensitivity. 
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2.2 Purpose of study 
The effect of low doses of the two main soy isoflavones genistein and daidzein on adipogenesis 
and GLUT4 expression has not been established. Most of the studies conducted on the effect of 
genistein and daidzein on fat cells have considered relatively high concentrations of individual 
soy bioactive compounds (50 µmol/L and higher). These supra-physiological concentrations 
increase lipolysis, which could be a potential problem in organs like the liver because an increase 
lipolysis would increase the amount of FFA taken up by the liver, which could contribute to the 
production of reactive oxygen species (ROS). Also, adipocytes secrete adipokines that have 
important cellular actions; apoptosis of adipocytes might affect adipokine functions [5].  
However, clinical studies have shown the beneficial effect of soy isoflavones consumption on 
obesity and diabetes. Animal and human studies have been conducted to investigate anti-diabetic 
effects of soybeans and their actions [10; 11; 12; 13]. Soya-containing diets were associated with 
an improvement in insulin resistance and glycemic control [14]. Since these two are the main soy 
isoflavones and soy isoflavones have been shown to decrease obesity and diabetes in 
epidemiological studies, we hypothesize that this beneficial effect may be due to the combined 
effect of those two compounds. Our objective here is to determine the extent to which the 
combination of low doses of genistein and daidzein exerts an effect on adipocyte differentiation 
and gene expression. Our central hypothesis is that genistein and daidzein combined at low 
doses will promote preadipocytes differentiation into adipocytes, as demonstrated by an increase 
in lipid content, adipocyte specific gene expression and GLUT4 expression, which is mediated by 
altering specific Wnt expression.  
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2.3 Materials and Methods 
2.3.1 Cell Culture Model and Treatments 
For the differentiation of 3T3-L1 preadipocytes, cells were grown to 100% confluence in Growth 
Media [DMEM (high glucose), 10% Calf Serum, 1% Penicilin/ Streptamycin] replaced every 
two days. At two days post-confluence, growth media was changed to Differentiation Media 
[DMEM (high glucose), 10% Fetal Bovine Serum, 1% P/S, 1% Insulin, 1% 3-Isobutyl-1-
methylxanthine 11.5mg/ml, 0.01% Dexamethasone 3.9mg/ml] in the presence or absence of 
genistein and daidzein. The combination of 3-Isobutyl-1-methylxanthine (MIX), dexamethasone, 
and insulin is known as the standard MDI adipogenic cocktail. At two days post-MDI induction, 
media was replaced every two days with post-differentiation media [DMEM (high glucose), 10% 
Fetal Bovine Serum, 1% P/S, 1% Insulin, +/-genistein + daidzein]. 3T3-L1 preadipocytes 
generally reach 80% differentiation 4 to 6 days post-differentiation.  
 
2.3.2 Oil Red O Staining of Lipids 
Cells were harvested on desired days and underwent Oil Red O Staining to quantify lipid 
accumulation, as it is an indirect determiner of cell differentiation. Cells, grown on 6-well plates, 
were treated with 10% formaldehyde in phosphate buffer solution (PBS) for 1 hour, washed with 
60% isopropanol, and completely dried. Then, cells were stained with 0.5% Oil Red O solution 
in 60:40 (v/v) isopropanol: H2O, for 30 minutes at room temperature. Finally, wells were rinsed 
with distilled water and dried. Optical density was then measured at 490nm, after eluting with 
isopropanol, to quantify lipid accumulation. 
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2.3.3 RNA Isolation and Analysis 
Cells washed with phosphate buffer solution (PBS), were harvested with Trizol Reagent and 
stored at -80° C until mRNA isolation. For isolation, samples were thawed and centrifuged with 
200µL chloroform. Supernatant was transferred to a fresh tube and centrifuged with isopropanol 
(1:1) to precipitate RNA. Isopropanol was removed and the pellet was washed three times with 
ethanol by centrifugation. The pellet was then re-suspended in DEPC water and quantified using 
a spectrophotometer at 260 nm. 8µg of RNA was used along with SuperScript III reagents to 
make cDNA which was stored at -4°C. Polymerase Chain Reaction was performed with primers 
for PPARγ, C/EBPα, GLUT4, Wnt5b and Wnt10b (see Table 2). Samples were run on an 
agarose gel, and detected using Ultra Violet light. Band intensity was determined using Image J 
analysis and adjusted to β-actin. 
 
Table 3. Primer Information 
genes 
primers  Temperature/Cycle 
 sense 5'-3'  antisense 5'-3' 
 
β-actin  AGGCTGTGCTGTCCCTGTATGC 
 
ACCCAAGAAGGAAGGCTGGAAA 60/40 
 
GLUT4 GATTCTGCTGCCCTTCTGTC ATTGGACGCTCTCTCTCCAA 51/40 
 
PPARγ CCAGAGTCTGCTGATCTGCG 
 
GCCACCTCTTTGCTCTGATC 57/40 
 
Wnt5b GTGCCAACACCAGTTTCGAC 
 
CTCTCGGGCATCCACAAACT 57/40 
 
Wnt10b CTGACTTCTGCGAGCGAGAC 
 
CAGCACCAGTGGAAACGACAG 58/40 
 
C/EBPα GGTGCGCAAGAGCCGAGATAAAG 
 
AGTTCACGGCTCAGCTGTTCCAC 61/40 
 
 
2.3.4 Statistical Analysis 
Samples were collected in duplicate, and differences between the means were determined by 
student’s T-test. P-values were considered significant at <0.05.  
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2.4 Results 
2.4.1 Effect of genistein, daidzein and their combination on adipocyte differentiation  
In order to determine the dose-dependent effect of soy isoflavones, post-confluent 3T3-L1 cells 
were grown and differentiated in the presence or absence of either genistein, daidzein or 
combined genistein and daidzein for 8 days, upon which they were harvested for Oil Red O 
staining to measure lipid accumulation. Rosiglitazone, a TZD molecule, was used as a positive 
adipocyte differentiation control. Cells not treated with differentiation cocktail served as negative 
controls. As shown in Fig. 6, genistein increased adipoyte differentiation at concentrations 
between 1 and 20 µmol/L. However the increase is not statistically significant. Daidzein 
treatments at all concentrations increased adipocyte differentiation with a significant increase at 
20 µmol/L (1.8 fold) as shown in Fig.6. When combined, genistein and daidzein treatments 
significantly increased adipocyte differentiation compared to the negative control with a greater 
increase obtained with 20 µmol/L treatment (2.4 fold). The combination seems to increase more 
adipocyte differentiation compared to the individual compound but the increase is less than that 
of rosiglitazione, the antidiabetic drug. 
 
  
 
Figure 6. Genistein, daidzein and their 
accumulation in 3T3-L1 preadipocytes
Absorbance of red fat-soluble stain eluted with 100% is
fold changes, compared with control (vehicle), which was arbitrarily set to 1. Each value is the Mean±S.E.M. of the 
results from two different plates and is representative of results from at least two different experiments. Means 
without a common letters are significantly differ
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Figure 7. PPARγ mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) 
or their combinations (C). 
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying 
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L) 
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR.  PPARγ mRNA levels were quantified and 
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which 
was arbitrarily set to 1; one independent experiment. 
 
 
 
C/EBPα mRNA expression was not enhanced in 3T3-L1 cells differentiated with MDI plus 
either genistein or daidzein alone (Fig.8A & B). However, an increase in C/EBPα mRNA 
expression was observed when 3T3-L1 cells were treated with genistein and daidzein combined 
at a concentration of 20 and 50 µmol/L (Fig. 8C).  
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Figure 8. C/EBPα mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) 
or their combinations (C). 
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying 
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L) 
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR.  PPARγ mRNA levels were quantified and 
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which 
was arbitrarily set to 1; one independent experiment. 
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Figure 9. GLUT4 mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) 
or their combinations (C). 
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying 
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L) 
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR.  PPARγ mRNA levels were quantified and 
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which 
was arbitrarily set to 1; one independent experiment. 
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2.4.4 Effects of Genistein, daidzein and their combination on the Wnt signaling pathway  
In Order to determine whether soy isoflavones effects on adipocyte differentiation is mediated 
through the Wnt-β signaling pathway, we determined the mRNA expression of Wnt-5b which is 
adipogenic and Wnt 10 b which represses adipocyte differentiation. Soy isoflavones slightly 
increase the expression of Wnt-5b compared to control cells at 20 µmol/L (Fig.10) 
 
                                      
 
               
                                                                        
                                                                       
 
 
          
 
                                                  
                                                  
 
1
0.9 0.91
0.97
1.3
0.47
1.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
MDI 1uM 5uM 10uM 20uM 50uM Rosi
g
e
n
e
 e
x
p
re
ss
io
n
Genistein treatments
Wnt5b expressionA 
0       1           5         10          20         50         Rosi 
Genistein 
Concentrations (µmol/L) 
β-Actin 
PPARγ 
  
35 
 
 
 
 
                         
                        
 
 
 
 
 
                      
                                                                         
 
 
 
Figure 10. Wnt5b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B) 
or their combinations (C). 
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying 
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L) 
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR.  PPARγ mRNA levels were quantified and 
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which 
was arbitrarily set to 1; one independent experiment. 
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 soy isoflavones treatments, however, rosiglitazione 
10b (Fig.11). 
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Figure 11. Wnt10b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein 
(B) or their combinations (C). 
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying 
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L) 
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR.  PPARγ mRNA levels were quantified and 
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which 
was arbitrarily set to 1; one independent experiment. 
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2.5 Discussion 
Epidemiological data and clinical studies in humans have shown that higher intake of dietary soy 
isoflavones correlate with lower incidence of diabetes and improved insulin sensitivity [77,78]. 
In vitro cell culture studies however have showed controversy effects of soy isoflavones on the 
activation of PPARγ, a nuclear transcription factor and expression of its downstream target genes 
[59, 60, 78] mainly due to supra-physiological concentrations.                           
It is unclear whether potential benefits are mediated by the additive effects of multiple 
isoflavones components or the concentration of a single isoflavone because most clinical studies 
have used soy protein containing several different isoflavones.  
Here we showed that soy isoflavones stimulated adipocyte differentiation using the 3T3-L1 cell 
line, a well-established in vitro model of adipocyte differentiation that is more sensitive and thus 
more responsive to physiological doses. We further showed that when combined, daidzein and 
genistein increased more lipid accumulation at lower dose than individual compounds (Fig.6).  
Dong X et al [83] have shown that when combined, genistein and daidzein at low dose has a 
preventive synergistic effects on human prostate cancer compared to individual compound. 
However, to our knowledge, this is the first data to show the additive effect of soy main 
isoflavones on adipocyte differentiation. 
The effects of soy isoflavones whether alone or combined on adipocyte differentiation were 
comparable with regard to PPARγ mRNA expression particularly at 20 µmol/L, but does not 
completely correlate with C/EBPα mRNA expression. From our data, due to the limited sample 
size, we can only suggest that there is a trend that the increase in adipocyte differentiation by soy 
isoflavones, correlate with the expression of the key adipocyte transcription factor, PPARγ 
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especially at 20µmol/L (Fig.7). Kae Won Choa et al [58], similarly showed that daidzein and its 
metabolite equol enhance PPARγ expression at low doses. The anti-adipogenic effect of 
genistein at 50 µmol/L that we observed has also been reported. Genistein at both 50 and 100 
µmol/L has been shown to inhibit adipogenesis of 3T3-L1 cells [83], presumably through its 
inhibitory effects on tyrosine phosphorylation of multiple signaling molecules.                       
Because  PPARγ is the molecular target for TZD antidiabetic drugs that improve insulin 
sensitivity and since insulin-stimulated glucose transport is regulated by expression of key 
insulin signaling molecules such as GLUT4 [81], we have examined whether soy isoflavones 
would affect the expression of GLUT4 expression at mRNA level. There is a trend that genistein 
and daidzein alone or combined increased expression of GLUT4 mRNA; the stimulatory effect 
of the combination was greater than that of individual compounds (Fig. 9), indicating that the 
enhanced insulin sensitivity and glucose uptake observed in intervention studies by soy 
isoflavones may be mediated in part by up-regulation of GLUT4 expression.   
Since Wnt10b has been shown to be anti-adipogenic, and Wnt5b has been shown, when present, 
to repress the anti-adipogenic effect of Wnt10b, we determined whether the effect of soy 
isoflavones on adipocyte differentiation would be mediated by the Wnt signaling pathway. Our 
data showed that there is a trend that genistein and daidzein alone or combined do not affect 
Wnt10b mRNA expression while at 20 µm/L Wnt5b expression seems to be up-regulated. 
However the antidiabetic drug, rosiglitazione seems to exert its anti-diabetic effect through the 
inhibition of Wnt10b expression (Fig.11). This observation is consistent with studies that have 
shown that TZD drugs inhibit Wnt signaling pathway [84]. 
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CHAPTER3 
CONCLUSION & FUTURE DIRECTIONS 
3.1 Summary 
There is a strong link between obesity and T2DM. In insulin resistant states, such as obesity and 
type 2 diabetes, fat depots contain a high proportion of large-lipid filled adipocytes that are 
poorly functioning. It is therefore necessary to ensure the differentiation of newly formed 
adipocytes that are highly insulin sensitive in order to prevent T2DM. There have been 
increasing efforts to identify natural compounds to be used as anti-diabetic products with fewer 
side effects [77]. Epidemiological data strongly suggest that consumption of soy is associated 
with reduced incidence of diabetes and T2DM-related symptoms [79,80], which has led the Food 
and Drug Administration to approve cardiovascular health claims for soy protein intake.    In 
summary, our results suggest that soy isoflavones genistein and daidzein alone or combined 
increased adipocyte differentiation particularly at a concentration of 20µm/L. The stimulation of 
adipocyte differentiation is even greater when the two individual compounds are combined 
indicating a potential additive effect.                                                                          .             
Adipocyte differentiation is enhanced through PPARγ activation and the downstream responses 
to PPARγ activation include increase in the expression of GLUT4 mRNA, which might explain 
the enhanced glucose uptake and insulin sensitivity associated with soy consumption. However, 
from our data, soy isoflavones effect on Wnt signaling pathway is unclear. Genistein and 
daidzein alone or in combination did not show an effect on the anti-adipogenic Wnt signal, 
Wnt10b while there is a trend that Wnt5b expression is up-regulated by soy isoflavones at 
mRNA levels. Further studies are needed to elucidate the mechanisms of combined soy 
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isoflavones effect on adipocyte differentiation and Wnt signaling pathway both at mRNA and 
protein levels at early and late stage of the differentiation process. 
 
3.2 Limitations 
There are some limitations of the work presented here that are important to discuss. First is that 
we use only one cell line to elucidate the mechanism through which soy isoflavones might exert 
their effect on adipocyte differentiation. It is important to use other cell types to see if the 
concentrations used and the responses observed vary according to cell types. However, 3T3-L1 
cell lines constitute a good model to study the mechanisms in vitro.  
A second limitation is that we only looked at the mRNA expression and we did not analyze 
protein expression. The responses at mRNA levels may be different from that at protein levels. 
 A third limitation is the semi-quantitative nature of the regular PCR we used, which is a less 
precise quantification compared to Real-Time PCR. Nonetheless, regular PCR has been used by 
many researchers and allowed to understand many in vitro mechanistic aspects of isoflavones 
action. 
Another limitation is sample size. Most of the work presented here is in the preliminary stage 
and needs to be repeated in order to gain statistical significance. However we were able to gain 
valuable insight from these initial findings and open the door to a number of research questions 
that could be addressed in the future.  
Finally a major limitation not encountered here but commonly encountered with human 
supplementation trials of soy isoflavones is bioavailability. Even though pharmacological doses 
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of soy isoflavones might be able to be used, absorption is still variable from individual to 
individual because of the gut microflora’s ability to metabolize the isoflavones. One possible 
way to overcome this limitation is through the use of nanoparticle isoflavones delivery. 
 
3.3 Significance of Findings 
In vivo animal studies have shown soy isoflavones to ameliorate metabolic syndrome, 
specifically insulin resistance, hyperglycemia, and weight gain. Our findings here of soy 
isoflavones effect on adipocytes help understand the mechanisms behind their in vivo effects. 
The significance of this work is that it focuses on a possible simple nutritional intervention that 
could safely ameliorate the adverse insulin resistance associated with obesity by enhancing 
adipocyte differentiation and insulin sensitivity. The new knowledge generated from these 
preliminary data will be beneficial by giving an important piece of the scientific foundation that 
could bring new avenues of investigation, prevention and possible treatment of obesity-
associated insulin resistance, and thereby help lessen the adverse health burden of obesity. 
 
3.4 Future Research Directions 
Although our findings here suggest soy isoflavones increase adipocyte differentiation specially 
when combined through PPARγ and Wnt5b up-regulation, this effect should be further 
confirmed in vitro through the use of (1) a more accurate mRNA quantification method, Real 
Time-PCR, (2) Western blotting, to determine the response at protein levels, (3) both at early and 
late stage of the differentiation process and (4) through the use of human cell lines that may 
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behave differently than 3T3-L1 pre-adipocyte because of pluripotency stage. Once soy 
isoflavones effect has been confirmed in vitro, animal studies should be employed in order to 
determine soy isoflavones ability to increase adipogenesis and glucose uptake in various adipose 
depots (subcutaneous and visceral adipocytes). This will allow to determine optimal soy 
isoflavones intake needed to maximize health benefits. 
To further confirm our preliminary findings, our experiments should be repeated to gain validity.  
Next it would be of interest to determine the relationship between the effect of soy isoflavones 
on adipocyte differentiation and Wnt signaling. The downstream genes of Wnt signaling c-myc 
and cycline D1 expression should be determined both at mRNA and protein levels. Also β-
catenin phosphorylation could be determined by studying the kinase activity. Finally, soy 
isoflavones could be used in the presence and absence of a Wnt inhibitory agent to further 
elucidate the mechanism(s) of Wnt dependency.  
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